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Abstract.  Bcl-2 is a mitochondrial- and perinuclear- 
associated protein that prolongs the lifespan of a vari- 
ety of cell types by interfering  with programmed cell 
death (apoptosis).  Bcl-2 seems to function in an an- 
tioxidant pathway,  and it is believed that membrane at- 
tachment mediated by a COOH-terminal hydrophobic 
tail is required for its full activity. To identify critical 
regions in bcl-2c~ for subcellular localization,  activity, 
and/or interaction  with other proteins,  we created, by 
site-directed mutagenesis, various deletion,  truncation, 
and point mutations.  We show here that membrane at- 
tachment is not required for the survival activity of 
bcl-2ot. A  truncation mutant of bcl-2ot lacking the last 
33 amino acids (T3.1) including the hydrophobic 
COOH terminus  shows full activity in blocking apop- 
tosis of nerve growth factor-deprived sympathetic neu- 
rons or TNF-o~-treated L929 fibroblasts. Confocal mi- 
croscopy reveals that the T3 mutant departs into the 
extremities of neurites in neurons and filopodias in 
fibroblasts. Consistently, T3 is predominantly detected 
in the soluble fraction by Western blotting, and is not 
inserted into microsomes after in vitro transcrip- 
tion/translation.  We further provide evidence for mo- 
tifs (S-N and S-I/) at the NH2 and COOH terminus  of 
bcl-2, which are crucial for its activity. 
I 
N both vertebrates and invertebrates,  cell numbers are 
controlled by a balance between cell renewal and cell 
death. Any disruption of this balance may result in neo- 
plasia.  Whereas cell proliferation and its aberrances have 
been extensively studied,  relatively little is known about the 
regulation of cell death (20, 51). Cell death can occur by two 
distinct mechanisms,  apoptosis or necrosis.  In the former 
case, the cell actively participates in its own demise, charac- 
terized by plasma membrane blebbing, cell volume loss, nu- 
clear  condensation,  and  endonucleolytic  degradation  of 
DNA into nucleosomal intervals  (DNA ladder) (67).  It is 
now clear that apoptosis occurs under a wide range of pri- 
marily physiological processes, including the removal of in- 
terdigital  cells during embryonic digit formation  (32),  the 
elimination  of massive numbers  of neurons  generated  in 
early developments  to ensure refinement  of connections at 
later stages (52),  the deletion of autoreactive T and B cell 
clones during maturation (54), the formation  of diverse im- 
mune cells from progenitor cells (54), the involution or self 
renewal  of  epithelial  tissues/glands  (28),  and  in  tumor 
Address correspondence to J/irg Tschopp,  Institute of Biochemistry,  Che- 
rain des Boveresses  155, CH-1066  Epalinges,  Switzerland. 
The present address for Christoph Borner is Institute of Biochemistry, 
University of Fribottrg,  Ptrolles, CH-1700  Fribourg, Switzerland. 
C. Borner and I. Martinou contributed equally to this work and should 
therefore be considered first authors. 
regression (66). In all these cases, the purpose of apoptosis 
is to actively remove superfluous cells, cells with inappropri- 
ate specificity or developmental capacity,  or cells that have 
already served their purpose (20, 52, 54). This removal of 
cells is achieved  by changing  the levels  of hormones and 
growth factors in the cellular environment. 
Although  many of the extracellular  signals  that regulate 
apoptosis in different cell types have been identified,  the bio- 
chemical mechanisms  and identities  of the gene products 
responsible for this process are only now being elucidated 
(16, 20, 24, 51). Genetic analysis of the nematode Caenor- 
habditis elegans has led to the identification of several genes 
that affect various steps in programmed cell death occurring 
during development.  The ted-3 and ced-4 genes are thought 
to be necessary for apoptosis to occur because mutations 
that inactivate  either of these result in the survival  of cells 
that would otherwise die (19). In contrast, the ced-9 gene ap- 
pears to function in preventing apoptosis because a gain-of- 
function mutation of this gene eliminates  apoptosis (30). 
This implies  that both effector and repressor genes will 
also exist in mammalian cell death pathways. One such mam- 
malian gene has been identified as bel-2. Bcl-2 has been iso- 
lated from follicular  B cell lymphomas where it is overex- 
pressed as a result of a t(14;18) chromosomal translocation 
(4, 14, 62). It represents a novel oncoprotein that appears to 
predispose cells for carcinogenesis  by enhancing  their life- 
span rather than their proliferation  (36, 41). Gene transfer 
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a variety of stimuli. It confers survival to certain hematopoi- 
eric cell lines after growth factor withdrawal  (35, 49, 63), 
protects primary  neuronal  cell cultures  (1,  26)  as well as 
PC12 (5) from degradation induced by nerve growth factor 
depletion, spares cells from death induced by irradiation (53, 
56), heat shock, ethanol,  methotrexate,  glucose and serum 
withdrawal,  membrane  peroxidation,  free-radical  induced 
damage (34, 39, 61, 68), TNF (31), and glucocorticoid (2, 
53, 56), extends the survival of virally infected cells to allow 
viral persistance (3, 44) and renders tumor cells markedly 
resistant to killing by a wide variety of antineoplastic drugs 
(46, 64). Redirection of bel-2 expression to cortical thymo- 
cytes in transgenic mice led to cells that were now resistant 
to glucocorticoid-,  T- irradiation-,  and anti-T  cell recep- 
tor-induced cell death (53, 56). 
Recent results point to an important role of bcl-2 in an an- 
tioxidant pathway (34, 39). How bel-2 exerts this function is, 
however,  still poorly defined.  A  major hint could provide 
four  recently  identified  proteins  that  interact  with  bcl-2 
(bcl-xs, bcl-xL, bax, and R-ras) (7, 22, 50). Two of them, 
bcl-xs and bax,  are bcl-2 homologues that can negatively 
regulate the survival activity of bel-2 in a dominant fashion 
(7, 50). Since bax can form heterodimers with bcl-2 in vivo, 
it is believed that the death-inducing  effect of the former is 
either caused by sequestering the latter or by directing the 
heterodimer to effectors of apoptosis instead of cell survival 
(50). It is, therefore, important to define the regions in bcl-2 
that interact with bax/bcl-xs or downstream effectors. 
Another unresolved issue is the intracellular site of action 
ofbel-2. In some cells, confocal microscopy and subcellular 
fractionation studies revealed an association ofbcl-2 with the 
mitochondrial membrane (35). A recent study by Nguyen et 
al. (48) indicates that the COOH-terminal,  hydrophobic 22 
amino acids of bcl-2 serves as a signal/anchor  segment to 
target bcl-2 to the outer mitochondrial membrane. In other 
ceils,  bcl-2 has mainly been locali7ed to the endoplasmic 
reticulum and the nuclear membrane (3,  12, 38, 45a). Con- 
sistent with the latter observation, bcl-2 was still able to pre- 
vent the death of cells that lacked mitochondria DNA and, 
thus, an intact respiratory chain (38).  These findings indi- 
cated that the action of bcl-2 may not be limited to one partic- 
ular subcellular region but might occur at numerous sites, 
depending on the cell examined. 
The bcl-2 gene can encode for two proteins,  bel-2o~ and 
bcl-2/3, which differ only in their carboxyl tails because of 
an  alternative  splicing  mechanism  (60).  Whereas  overex- 
pressed bcl-2/3 predominantly resides in the cytoplasm and 
lacks survival activity, bel-2o~ is membrane bound and capa- 
ble of conferring cell survival (58). This difference has been 
attributed to the presence of a hydrophobic domain in the 
carboxyl terminus of bcl-2ct (13), which is thought to act as 
a transmembrane anchor. Removal of this stretch has previ- 
ously been shown to mitigate the survival activity of bcl-2oL 
(3). A recent report by Hockenbery et al. (34), however, sug- 
gested that a soluble bcl-2 lacking this stretch may still exert 
partial  survival activity. 
In an attempt to define bcl-2 functional motifs, regions re- 
quired for subcellular localization and/or sites of interaction 
with  other  proteins,  we generated  bel-2  mutants  by site- 
directed mutagenesis  and examined  them for activity and 
subcellnlar distribution by microinjection into the nuclei of 
nerve growth factor (NGF)l-deprived neurons (26). 
Materials and Methods 
Cell Culture 
Sympathetic  neurons from superior cervical ¢,Rnslia of newborn rats were 
cultured as previously described (29). L929 murine fibrobiasts and their de- 
rivatives were maintained in RPMI medium supplemented with 10% fetal 
calf serum (Gibco Laboratories, Grand Island, NY). 
Antibodies 
A polyclonal antiserum _against  a 14-amino acid peptide encompassing do- 
main 2 of murine bcl-2 (GAAFFPGIFSFQPE) was generated in rabbits. 
The peptide was synthesized by the TASP method (23). For Western immu- 
noblotting, the bcl-2 antiserum dilution was 1:2,000, for immunocytochem- 
istry 1:200. Part of the antibody was affinity purified on nitrocellulose strips 
containing a  GST-bcl-2  fusion protein  as  described  before  (21).  The 
monospecific 27-4 antibody obtained was used at dilutions 1:500 for West- 
ern blots and 1:100 for immqnocytochemistry.  Secondary  antibodies were 
an alkaline phosphatase-conjugated goat anti-rabbit whole antibody for 
Western blots (Sitrma Immunc~hemicals, St.  Louis,  MO)  and a  FITC- 
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Labs.,  Inc., 
West Grove,  PA). 
cDNA Cloning and Construction of 
Expression Vectors 
The routine bol-2 eDNA was obtained by PCR amplification of a routine 
B~I T cell library using the primers GOTAC~rtt:rrrlt:OGGG 
and CGC~TTrGTCGACCTCACTTGTG.  Whereas a PstI site was 
introduced into the 3' primer, the 5' primer already contained a Pstl site up- 
stream of the ATG start codon. The amplified cDNA was cloned into the 
PstI site of pSK  + Blueseript (Stratagane,  La Jolla, CA), and the correct se- 
quence confirmed by sequencing. Subsequently, the bel-2 cDNA was cloned 
into the HiednI site of the retroviral vector, pMVI2 for eukaryotic ~pres- 
sion (kindly  provided by I.  B.  Weinstein and R.  S.  Kranss, Columbia- 
Presbyterian Cancer Center, Columbia University,  College of Physicians 
and Surgeons,  New York). lkl-2/psK  + was cut with Hindm and Sma and 
ligeted at the 5' end into the HindIII site of pMV12.  For site-directed  muta- 
genesis, the bci-2 eDNA was cloned into the EcoRV/XbaI site of pUC19M 
(Clontech, Palo Alto, CA), a derivative of pUC19 having the EcoRI site 
replaced by EcoRV. After mutagenesis and for microinjection into neurons 
and in vitro transcription/translatlon,  wild-type and mutant constructs were 
all subcloned into the EcoRI/XbaI sites of pcDNAI/amp (Invitrogen, San 
Diego, CA). In this vector, the expression of the bcl-2 cDNA is driven by 
the cytomegelovirus  promoter. 
Site-directed Mutagenesis 
Site-directed  mutagenesis was  carried out using the Transformer" site- 
directed mntagenesis kit from Clontech, according to the protocol provided 
by the manufacturer.  All the mutant bol-2 cDNAs were subeloned into the 
EcoRl/XbaI site (for PT3, EcoRV/XbaI) of the pcDNA I amp expression 
vector for in vitro tranacription/transiation  and microinjection  into neurons. 
The mutagenic primers for bel-2 mutagenesis were the following: 
DEL/:  (deletion of domain 1), resulting in the deletion of 78 bp (26 amino 
acids) between nucleotides (nt) 332 and 408 (Gly4-Glu29):  C~- 
AGGATGGC  ~~TCrffICKTJAGATGC  G; 
DE/2: (deletion of  domain 4), resulting in the deletion of 195 bp (65 Amino 
acids)  between nt698 and 894 (Phe127-Gly191):  TTCACCGCGAGG- 
GGACGCTGGGATGC cTrrGIUGAA; 
DEL3: (deletion F4.1 and FS), resulting in the deletion of 63 bp (21 amino 
acids) between nt 878 and 942 (Oln187-Phe207):  introduces a unique 
ClaI site:  CA1L"IUCAEACCTGGATCGA~C~TCT; 
DEL4: (deletion of the putative nuclear pore sequence), resulting in the de- 
letion of 18 bp (6 amino acids) between m 758 and 777 (Phe147-Gly152): 
~GGATTGTGGCCGCGGIW.ATGTGTG~GC 
1. Abbreviations used in this paper: NGF, nerve growth factor; nt, nucleo- 
tides; Rb, retinoblastoma gene product. 
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GTGGAGAGCG'ICAAC 
PT2: (point mutation of Cys226 to His226): GCCCTGGTC~CCAC- 
ATCACTCTGGGTGCA 
PT3: (point mutation of Tyr177 to Phe177): GCCCTGTCK3ATGACTGAA- 
TTCCTGAACC~TC'I'G 
T3.2 (truncation at nt 929 or Met203): CTATATCrCJCCCCAGCATGTGA- 
GGTCGAC&AACCTG-C 
T4: (truncation at nt 899 or Asp193, removes F5): GATAACGGAGC~TGG- 
GATTGAGGTC  GACAAAC  C TGC 
/5:  (truncation at nt 908 or Vail96): GGCTCJCd3A'IGCCTTTGTGTGA- 
GGTCGACAAACCTGC 
T6:  (truncation at nt 926 or Ser202):  GAACTATKIUGCCCCAGCTGA- 
GGTCGACAAACCTGC 
/7.'  (truncation at nt 923 or Pro201):  GTGGAACTATATGC_K2CCCTGA- 
GGTCGACAAACCTGC 
Three bel-2 mutations were generated as follows: For T1 (truncation at nt 
878 or 11e186), the bel-2/pSK  + was digested with BamH1, and the resulting 
576-bp fragment was directly cloned into the BamH1 site of the pcDNA 
I/amp expression vector.  Because the cloning site was not at a stop codon, 
T1 obtained one additional amino acid (H) encoded by 3' residing vector 
sequences.  T2 and T3.2 were similarly generated, but via HindH and SphI 
digestions, respectively. T2 (truncation  at nt 797 or Vail59) obtained the ad- 
ditional amino acids 1HHTC_~RSSMHLEGPIL,  whereas T3.1 (truncation 
at nt 929 or Met203) was extended by the amino acids HLEGPIL. 
Construction ofL929 Stably Overexpressing bcl-2 
CsCl-purified sense orientation pMV12 plasmids alone or carrying either 
full-length wild-type or T3.1 truncated mutant bcl-2 eDNA (10/~g) were 
transfected into subconfluent ~b2 cells with 25 #tg of lipofectin  (GIBCO 
BRL, Gaithersburg, MD) to produce recombinant routine Moloney retro- 
viruses (21). After 48 h, the culULre medium containing viruses was col- 
lected, filtered,  and stored at -70°C. 5  x  105 recipient L929 cells (sub- 
confluent) were infected with the virus-containing medium in the presence 
of 8 ~g/ml of polybrene. 48 h later, the cells were trypsinized and replated 
into medium containing 400 ~g/ml of hygromycin B (Calbiocbem-Novabio- 
chem Corp., La Jolla, CA). Resistant clones of L929 cells were picked by 
ring isolation after 2 wk of selection.  Clones and mixed cell populations 
were expanded and analyzed for bcl-2 expression by Western blots. Two cell 
lines overexpressing  either wild-type bcl-2 (L929bcl-2/5) or the T3.1 mu- 
tant (L929T3/3)  were used for further studies.  In addition, vector control 
lines were established (L929pMVI2/2). 
TNF-~-induced Apoptosis 
L929 or their derivatives expressing either wild-type or T3.1 bci-2 were 
seeded into 24-well plates at a concentration of 5  ×  105 cells/ml. After 
12 h, the cells were treated with 3 ng/ml mouse TNF-~x (Boehringer-Mann- 
heim Biocbemicals, Indianapolis, IN). At the times indicated, half of the 
cells per well were trypsinized, stained with trypan blue, and counted under 
the microscope to determine cell viability. In parallel, the other half of the 
cells was collected by centrifugation and washed in 20 mM Tris-HCl (pH 
8.0). DNA was phenol/chloroform extracted, treated with RNase (Boeh- 
ringer-Mannheim  Biochemicals) for 15 min at 37"C and electrophoresed on 
a 2% agarose gel to determine the degree of DNA ladder formation. 
Microinjection of bcl-2 cDNAs into Neurons and Cell 
Survival Assay 
Neurons were cultured in 3.5-cm diameter dishes for 7 d. Rectangles (10 
×  3 ram) containing 150-200 neurons were drawn on the bottom of each 
dish to allow localization of injected neurons. Doubly CsCl-purified circu- 
lar PeDNA I amp plasmids containing various bcl-2 mutant cDNAs were 
dissolved in H20 at a  concentration of 0.05/,g/ml.  Approximately 500 
DNA molecules were introduced into one cell nucleus with a low pressure 
microinjection system (automatic injector; Inject+Matic, Geneva) to en- 
sure high neuronal survival (25). 3 h after injection, the NGF-containing 
medium was replaced with NGF-free medium. The medium was changed 
daily.  Survival  of neurons was analyzed by morphological criteria. Neu- 
ronal death was clearly recognized by shrinkage and fragmentation of cell 
body and neurites (26). 
In Vitro Transcription and Translation 
In vitro transcription and translation was carried out exactly as described 
previously (13). eDNA fragments were cloned into the pcDNA I/amp ex- 
pression vector.  After linearization by NheI, the plasmids served as tem- 
plates for in vitro transcription of RNA using SP6 RNA polymerase (37) 
(Promega Corp., Madison, W1). RNA products (0.5 ~g) were translated in 
vitro using a rabbit reticulocyte lysate cell-free translation system (Promega 
Corp.) at 30°C for 45-60 min in the presence of 1 mCi/ml [35S]methio- 
nine, as previously described (37). Microsomal vesicles (Promega Corp.), 
at a concentration  of 3.0 eq/0.5 mg of initial RNA in a 25-/~1  translation reac- 
tion, were  included in the reticulocyte  translation reaction, and samples 
were incubated for an additional 30 rain at 30°C. Translation was terminated 
by the addition of cycloheximide  at a final concentration of 20/,g/ml. At 
this point, a membrane-stabilizing agent,  tetracaine (27),  was added to a 
final concentration of 2 raM, followed by 5 rain of incubation at 24°C.  All 
subsequent steps were carried out at 4°C.  Sedimentation of the membrane 
vesicles was performed at pH 8.0 and 11.5 as described (27) by layering the 
reaction mixture over a 0.5-M sucrose cushion and centrifuging in an alr- 
fuge (A100/18 rotor; Beckman Instruments, Inc., Fullerton, CA) for 5 rain 
at 20 p.s.i.  The entire superuatant solution (including the sucrose cushion) 
was removed, the membrane pellet was resuspended into the same volume, 
and both samples were analyzed by SDS-PAGE. As a positive control for 
translocation into microsomes, we concomitantly in vitro transcribed/trans- 
lated a ~-lactamase eDNA. 
SubceUular Fractionation 
Proteins were  extracted  as  follows:  Cells  were  washed three times in 
phosphate-buffered  saline,  and  either  immediately  lysed  in  preheated 
(95°C) extraction buffer A (20 mM Tris-HCl,  pH 7.5, 2 mM EDTA, 2 mM 
EGTA, 6 mM/~-mercaptoethanol, 2/tg/ml aprotinin, and 10 ~tg/ml leupep- 
tin) containing 1% SDS followed by sonication (total extracts) or scraped 
into ice-cold buffer A, lysed by sonication, and centrifuged at 100,000 g 
for 1 h, yielding the soluble cytosol and the particulate membrane pellet 
(8, 9). The particulate fraction was solubilized  in preheated buffer A con- 
taining 1% SDS. The protein content in these extracts was determined ac- 
cording to a modified  method of Bradford (10). 
lmmunoblot and Immunocytochemical Analysis 
Immunoblot analysis of the cytosolic,  membrane, and total extracts were 
perfomed exactly as described previously  (8, 9). Briefly, after SDS-POly- 
acrylamide gel electrophoresis on a 12 % acrylamide gel (43), proteins were 
electrntransferred (Bio Pad Laboratories, Richmond, CA) as described by 
Towbin et al. (59). The membrane was subsequently stained with 0.2 % Pon- 
ceau red to assure equal protein loading and transfer. Membranes were then 
incubated for 90 rain with primary bcl-2 antibodies in a  1:2,000 dilution 
(for monospectic  antibodies, 1:500) in blocking buffer. The immunocom- 
plex was visualized by colorization with alkaline phosphatase-conjugated 
goat  anti-rabbit secondary  antibodies  and  nitro  blue  tetrazolium  and 
5-bromo-4-clfloro-3-indoylphosphate  as substrates.  For immunocytocbem- 
ical analysis, microinjected neurons were kept in NGF-rich medium for 3 d, 
and L929 fibroblasts were grown in sernm-contalning  medium overnight on 
coverslips before bcl-2 immunoreactivity was measured.  Both types of cells 
were fixed in 3 % paraformaldebyde,  permeabflized in 0.05 % saponin in 
PBS, and incubated with anti-bcl-2 and then FITC-conjugated  goat anti- 
rabbit IgG antibodies. Immunolocalization of bel-2 was performed by a Bio 
Pad confocal  microscope. 
Results 
Generation of bcl-2 Mutants 
To decipher functional domains in bcl-2, we considered the 
following regions as targets for mutagenesis: (a) the COOH 
terminus  previously  implicated  in  survival  activity  and 
membrane targeting;  (b) stretches of amino acids including 
domain II (50) and two cysteines that are highly conserved 
between human, mouse,  and chicken  homologues of bcl-2 
(18); and (c) three motifs that have been shown in other pro- 
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Figure  1.  Strategy  of the  in 
vitro mutagenesis of bcl-2 and 
survival  activity  of the  mu- 
tants.  (A)  Murine  wild-type 
bcl-2c~ has  236  amino  acid 
residues  and  can be divided 
into  five domains,  based  on 
the varying  homologies  with 
bcl-2 of other species. Panic- 
ularly high sequence homolo- 
gies  are  found  at  the  NH2 
terminus (hatched region, do- 
main  S-N)  and  in  domain 
4 (filled boxes, S-I and S-II). 
C-terminal  to S-II is found a 
region  (S-II-C)  required  for 
functional  activity  of  bcl-2 
(stippled box). The filled box 
at the COOH terminus repre- 
sents the membrane interact- 
ing segment. (B and C) Struc- 
ture of bcl-2 mutants including 
various deletions (DEL), trun- 
cations (T), and point mutants. 
DELl and DEL2 mutants ex- 
hibit  structural  similarities 
with bax and  oclx-s,  respec- 
tively.  Survival  activity  was 
measured in neurons deprived 
of NGF or in L929 fibroblast 
exposed  to TNF-o~ (between 
parenthesis).  Localization  of 
bel-2 was determined by con- 
focal microscopy  in  neurons 
and  in  3T3  fibroblasts  (see 
Fig. 3). n.d.,  not determined. 
teins to serve as protein-protein interaction modules.  The 
latter include a variation of the so-called retinoblastoma gene 
product (Rb) binding "pocket" (LxCxE -DxxxLxDL/MxxL; 
in bcl-2: VxCxE - ExxxLxDNxxL) present in the adenovirus 
E1A, SV40 largeTAg, papillomavirus HPV ET, cyclin D, and 
Elf proteins (17, 65), the sequence EYLN found in the hu- 
man EGF receptor which,  when phosphorylated on tyro- 
sine,  interacts  with  the  signaling  molecule  Sem-5/GRB2 
(55),  and  a  putative  nuclear  pore  degenerate  sequence 
xFxFG present in pore proteins, such as p62, NUP1, nup153, 
and NSP1  (57). 
Survival Activity of bcl-2 Mutants 
The survival activities of the above described bcl-2 mutants 
were  examined  by  microinjecting  their  cDNAs  into  the 
nuclei of sympathetic neurons.  We have previously shown 
that  microinjection  of the  wild-type human  bcl-2  cDNA 
markedly enhanced the lifespan of these neurons in the ab- 
sence of NGF (26). Here, we show that this is also the case 
for the murine bcl-2 counterpart (Figs.  1 and 2). Whereas 
NGF-deprived neurons injected with the expression vector 
alone died by apoptosis within 3 d,  neurons injected with 
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Figure 2. Inhibition of neuronal and fibroblast cell death by bcl-2 
mutants.  (A) Viability assays: Neurons were microinjeeted with 
pcDNA I/amp(vector control), murine wild-type bcl-2c~, and T4, 
T5, and T3.1 mutants were deprived of NGE The percent viability 
was assessed by morphological criteria (shrinkage, fragmentation 
of cell bodies) after 6 d and represented as the mean  +  SEM 
(n =  3, 100-200  neurons each experiment). (B) Kinetics of cell 
viability: At several timepoints post NGF deprivation, the viability 
of neurons was assayed as described in A. Data are shown as the 
mean of three experiments. (C) Effects of bcl-2 on L929 cell sur- 
vival in the presence of TNF-c~. Cells were stably transfected with 
bcl-2 fully retained viability. The survival activity of bcl-2 
was maintained when the two conserved cysteines, Cys155 
(PT1) or Cys226 (PT2), were mutated to histidines (Fig. 1). 
Cys155 is contained within a putative Rb-binding pocket (17, 
65).  According  to  previous  findings  with  classical  Rb- 
binding proteins, this mutation should have ablated survival 
activity, if an interaction between bcl-2 and Rb would be 
necessary for bcl-2 function (17, 65). Cys226 is part of the 
COOH-terminal hydrophobic stretch. This residue has been 
implicated in the interaction of bcl-2 with membrane pro- 
teins (11). Our data indicate that such an interaction, if it in- 
deed occurs, has no significance for bcl-2 activity. No role 
for survival activity also appears to play a putative SH2 bind- 
ing domain in the central part of bcl-2. This is because point 
mutation of tyr177 (PT3), the critical residue for a possible 
interaction with an SH2 domain (55), does not alter the ca- 
pacity of bcl-2 to protect neurons from cell death (Fig.  1). 
In contrast, deletion of a putative nuclear pore degenerate se- 
quence (xFxFG) (DEL4) (57) did partly mitigate the survival 
activity of bcl-2 (Fig.  1). 
An interesting picture was obtained when we created dele- 
tions  and truncations  within  highly conserved regions of 
bcl-2. We focused our analysis on the NH~ terminus, the 
most conserved (up to 100%) internal part (domain 4), and 
the COOH terminus of bcl-2 (Fig.  1). Deletion of the first 
NH2-terminal 29 amino acids (S-N domain, DELl), as well 
as the removal of the internal domain 4  of bcl-2 (DEL2), 
fully destroyed the ability of bcl-2 to confer cell survival to 
NGF-deprived neurons (Fig. 1). Because in vitro translation 
analysis revealed no stable protein product of the DEL2 mu- 
tant (in contrast to DELl, data not shown), we cannot ex- 
clude that the lack of activity is simply caused by translation 
inefficiency. 
As previously described (3), removal of the last COOH- 
terminal 50 amino acids (truncation at Ile 186, T1) fully ab- 
lates the survival activity of bcl-2 (Fig. 1). A further trunca- 
tion at amino acid  159 (T2) had the same effect (Fig.  1). 
Truncation at Asp  193  (T4) had a mitigating effect on cell 
survival (Fig.  1). This mutated bcl-2 essentially resembles 
bcl-2~  without  its  unique  carboxyterminal tail  (Fig.  1). 
When truncations were applied further carboxyterminal to 
T4, i.e., in the region unique to bcl-2~, survival activity of 
bcl-2 was at least partly retained. "15, a truncation mutant at 
Vail96 rescued 18 %  (Fig. 2 A), wheras T7 (truncation at 
Pro201), T6 (truncation at Ser202) rescued NGF-deprived 
neurons from cell death as efficiently as wild-type bcl-2 (Fig. 
1). Consistent with these truncation mutants, deletion of Gin 
187-Phe207 (DEL3) fully ablated survival activity of bcl-2 
(Fig. 1). The deletion mutant was in vitro translated (data not 
shown) into a protein of correct size. 
The  most  intriguing  mutant  was  T3,  a  truncation  at 
Met203.  This mutant was constructed by two means  (see 
Materials and Methods):  (a) by restriction digest cloning, 
adding seven amino acids coded by the vector seqeunee be- 
fore the stop signal(T3.1), and (b) by site-directed mutagene- 
sis, introducing a stop codon after Met203 (T3.2). As ex- 
pected from the analysis of T7 and T6, T3.1 and T3.2 were 
pMV 12 (vector control), bcl-2 wild type, and its soluble mutant 
T3.1. The percent of cell viability was assessed by trypan blue ex- 
clusion. Data are shown as mean +  SEM of three experiments. 
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type bcl-2 and its COOH terminal trun- 
cated form. (A) lmmunofluorescent con- 
focal microscopy of neurons microinjected 
with wild-type bcl-2 (left panel) and the 
trun~ted mutant T3.1 (right  panel). Serial 
section of 0.2/zm are shown in the lower 
panels. Bcl-2 was detected using affinity 
purified  mouse  bcl-2-specific  antibody 
27.4.  (B) Immunofluorescent and phase 
contrast  confocal microscopy of  L929 
fibroblast  stably transfected with wild-type 
bcl-2 (left  panels) and the truncated mu- 
tant T3.1 (right  panels). The arrows point 
to the tip of  the processes that accumulate 
the soluble form of bcl-2. Bars, 25 ~,M. 
at least equally active as wild-type bcl-2 when injected into 
neurons (Figs.  1 and 2).  Taken together, our mutagenesis 
studies revealed that the carboxy-terminal membrane attach- 
ment domain is not required for bcl-2 activity. 
To obtain further evidence that truncation mutants lacking 
the hydrophobic COOH-terminal tail of bcl-2 exhibit sur- 
vival activity, we stably overexpressed T3.1  in L929 fibro- 
blasts. Consistent with a previous report (31), treatment of 
L929 cells with 3 ng/mi of mouse TNF-ct triggers apoptosis 
(Fig. 2). Based on trypan blue exclusion staining, we found 
that only 18 % of the cells survived such treatment for 24 h. 
Overexpression of the wild-type murine bcl-2, however, ex- 
tended survival to 60%  (Fig. 2). As in the neuronal assay, 
the T3.1 mutant was as active as wild-type bcl-2. Its overex- 
pression protected up to 75 % of the fibroblasts from TNF- 
induced cell death after 24 h of treatment (Fig. 2  C). This 
was seen with three independent cell clones expressing high 
levels of the construct as well as in a mixed cell population 
of overexpressers (data not shown). Overexpression of wild- 
type bcl-2 and the T3.1 mutant also led to a drastic delay of 
TNF-mediated DNA fragmentation in these cells (data not 
shown). 
Bax was shown to regulate the activity of bcl-2 in a domi- 
nant negative fashion, most likely by forming heterodimers 
(50). Although bax and bcl-2 display a high overall sequence 
similarity, bax is lacking 25 residues close to the NH2 ter- 
minus. Because our DELl mutant resembled the structure 
of bax with respect to this deletion (Fig.  1, DELl, residues 
4-29; BAY, residues 7-31 ), we tested whether the absence 
of the corresponding amino acids could explain the inhibi- 
tory activity of Bax on bcl-2.  Bcl-2  remained,  however, 
equally active when coinjected into neurons with an excess 
of DELl mutant,  indicating that additional structural fea- 
tures are required for heterodimerization (data not shown). 
Negative  results  were also  obtained  when  the  bcl-x,-like 
mutant DEL2 was assayed for its inhibitory activity on bcl-2 
(data not shown). 
Association of  bcl-2 Mutants with Subcellular 
Structures In Viw 
Since the hydrophobic 26 amino acids at the carboxy termi- 
nus were found to constitute a transmembrane domain that 
anchors bcl-2 in the intracellular membranes (11), it was im- 
portant to investigate whether its absence in the active trun- 
cation mutants was associated with an altered subcellular 
The Journal of Cell Biology,  Volume 126. 1994  1064 Figure 4. Western blot analysis of  wild-type bcl-2 and the truncated 
T3.1 mutant. L929 fibroblasts stably overexpressing wild-type or 
T3.1 mutant bcl-2 were separated into heavy membranes (m) and 
cytoplasm (cy), and the bcl-2 was detected by Western blot analysis. 
distribution. We embarked on two strategies to monitor the 
subeeLlular distribution of our mutants: (a) immunolocaliza- 
tion in intact cells; and (b) detection by Western blot analy- 
ses of fractionated cellular extracts. 
For immunocytochemical studies, we injected the various 
mutant cDNAs into sympathetic neurons or analyzed L929 
fibroblasts  stably  overexpressing  the  mutants.  We  recog- 
nized the previously reported (35), punctuated staining char- 
acteristic of mitochondria in cells injected with wild-type 
bcl-2 (Fig. 3 A). This was best observed in L929 cells where 
the nuclear background staining was weak (Fig. 3 B). By 
contrast,  the  T3.1 mutant bel-2  associated  with  cellular 
structures  not  previously  seen  with  wild-type bcl-2  im- 
munofluorescence: neurite extensions in neurons (Fig. 3 A) 
and filopodias in fibroblasts (Fig.  3 B). This is consistent 
with a release of T3.1 from intracetlular membrane struc- 
tures and a departure to cellular extremities. 
Consistent with this notion, Western blot analyses of cyto- 
solic and membrane extracts from L929 cells stably overex- 
pressing either wild-type or T3.1 bel-2 demonstrated that 
while the 26-kD wild-type bcl-2 mainly associated with the 
particulate fraction, the 24-kD T3.1 is predominantly solu- 
ble (Fig. 4).  It should be noted, however,  that association 
with the respective compartment is not absolute. Approxi- 
mately 10-20% of wild-type bcl-2 appears to be soluble un- 
der normal growth conditions (Fig. 4).  A small portion of 
T3 also remains membrane attached (Fig. 4). 
Membrane Association of  bci-2 Mutants In Vitro 
The removal of the carboxyl terminal hydrophobic stretch 
has been shown to create a form of bel-2 that is incapable 
of inserting into microsomes after in vitro translation (13). 
Wild-type and mutant bcl-2 cDNAs used for microinjection 
into neurons (cloned into PeDNA I amp) were, therefore, 
subjected  to  T7  polymerase-directed  in  vitro  transcrip- 
tion/translation in the presence and absence of microsomes 
(cotranslational insertion) (Fig. 5). In this method, ~-lacta- 
mase, a signal peptide-containing protein normally translo- 
cates into the microsomes (Fig. 5). Surprisingly, in contrast 
to a previous report (13),  wild-type bcl-2 did not partition 
completely into the microsomal fraction. At least 30% of the 
in vitro-translated wild-type protein and even 50 % of the 
TI,'I2 mutants were recovered in the supernatant (Fig. 5). In 
contrast, the T3.1 mutant was fully recovered in the superna- 
tant (Fig. 5). 
Discussion 
Domain 4 of bcl-2 contains two highly conserved segments 
(S-I and  S-H) and three regions with similarity to known 
functional motifs, i.e. an Rb-binding pocket, an SH2 binding 
domain and a nuclear pore degenerate motif. Our mutagene- 
sis studies speak against an involvement of the Rb- and SH2- 
binding motifs in the survival activity of bcl-2. In contrast, 
the excision of the putative nuclear pore sequence led to a 
partial loss of activity (',,20 %). This raises the possibility of 
a role for bcl-2 in some aspect of nuclear transport, nuclear 
pore complex formation, or nuclear envelope assembly or 
maintenance. Consistent with this notion is the recent im- 
munolocalization of bcl-2 to patches of the nuclear envelope 
that are highly reminiscent of nuclear pore complexes (42). 
We can, however, not exclude that the removal of  the putative 
nuclear pore sequence simply distorts the structure of  the ad- 
jacent extremely conserved S-I segment, which is thought to 
be of functional importance (50). 
The NH2-terminal  region (S-N)  is highly conserved be- 
tween the bel-2 of different species and bcl-x, suggesting a 
role in protein-protein interaction. Indeed, the deletion of  26 
amino  acids  (residues  4-29)  at  the  NH2  terminus  corn- 
Figure 5. In vitro synthesis of wild-type and mu- 
tant bel-2. In vitro synthesis of bcl-2 and its trun- 
cated mutants, T1, 1"2, and T3. cDNAs were tran- 
scribed, and the resulting RNAs were translated  in 
vitro using rabbit  reticulocyte lysate containing 
[35S]methionine in  the  presence of microsomai 
vesicles. Membrane associated protein  (p)  was 
separated from soluble proteins(s) by high speed 
centrifugation at pH 11.5. Samples were analyzed 
by SDS-PAGE and by fluorograpby. The two left 
lanes are controls with/3-1actamase, which trans- 
locates  into  the  lumen of microsomes thereby 
liberating  its signal peptide  (reduction  of molecu- 
lar mass). At pH 11.5, microsomes lose their lumi- 
nai content, and ~-lactamase is recovered in the 
soluble, nonmembranous fraction. 
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Figure 6. Structure-function analysis and regions of homology between mouse bcl-2 and related mammalian and viral genes. The COOH- 
terminal amino acid sequences for mouse and human bcl-2cx, mouse bcl-2/~, mouse and human Bax, human bcl-x, and bcl-x], human 
mcl-1, mouse A1, African swine fewer virus LMW5-HL, Epstein-Barr virus BHRF1, and a hybrid human bcl-2-IL-2 receptor transmem- 
brane region were aligned (references 7, 15, 40, 45, 47, 50, 60, see text). The region with highest homology (S-H) and its adjacent function- 
ally important COOH-terminal extension (S-II-C) are boxed. A predicted hydrophobic  domain and adjacent charged residues are present 
in most members of the superfamily and are indicated by underlining and outlined characters, respectively.  Residues identical to the mouse 
sequence are shown with (:), while conserved (hydrophobic and charged) amino acids are bold typed. 
pletely impaired the survival activity of bcl-2. Because the 
translation of this mutant was efficient in vitro, a crucial role 
of the  NH2-terminal  residues  for the  survival activity is 
likely. Interestingly, bax, which induces rather than prevents 
cell death, lacks this particular S-N domain. 
Our results provide clear evidence that a stretch of amino 
acids within domain 4 (S-II) and its COOH-terminal exten- 
sion delineated by Asp186-Vail  96 at the beginning of domain 
5 (S-H-C) is crucial for its function (Fig. 5). The S-II region 
is highly conserved not only among different bcl-2 homo- 
logues (bax, bcl-x, and bcl-2/3) (7, 50, 60) but also among 
other putative cell survival factors. These include MCL1 
(40), a gene product involved in programmed myeloid cell 
differentiation, A1  (45),  a  hemopoietic-specific early re- 
sponse gene, and BHRF1 (15) and LMW5-HL (47), two viral 
genes involved in the survival of host cells during productive 
and/or persistent infections of Epstein-Barr virus and Afri- 
can  swine  fever  viruses,  respectively.  The  S-II  region 
(Trp185-Trp192) is especially intriguing because it is located 
just before the site where bcl-2ot and bcl-2/~ are differentially 
spliced (Fig. 6). Given the finding that our mutant T4 (ends 
at Asp193) is inactive in conferring cell survival, it is likely 
that this amino acid stretch alone is not sufficient for survival 
activity. It becomes fully active only when joined to at least 
five to nine additional residues. This extension probably as- 
sures the structural and functional integrity of the S-II seg- 
ment.  Indeed,  the  mutant  T7  (additional  nine  residues, 
Asp193-Pro201)  was as functional as the wildtype, whereas 
the addition of only 4 amino acids (mutant T5, 193-196)  led 
to only partial recovery.  Considering that the S-II-C seg- 
ments of the highly active BHRF1 protein (Fig. 5) and bcl-2 
display only little sequence similarity, no or little sequence 
requirements seem to exist for this segment. 
In view of the recent identification of bcl-2 homologues 
that regulate the extent ofbcl-2,~ activity through hetero- and 
homodimer formation (50), it is conceivable to propose that 
the herein defined functional S-II/S-II-C domain could medi- 
ate dimerization. This region is well situated to generate 
splice variants that would still dimerize but exhibit different 
activities. Varied dimerization between different partners is 
a common mechanism for regulating cellular functions (e.g., 
transcriptional activity; reference  6).  Such  a  mechanism 
would also provide a satisfactory explanation for the domi- 
nant negative action of bax (50) on the survival activity of 
bcl-2. In this respect, bax would form an inert heteromeric 
complex with bcl-2 similar to transcription factors that lack 
a DNA-binding or transactivation domain ("squelching"). In- 
terestingly, bax has retained the S-II domain but exhibits a 
distinct putative S-II-C domain (50) (Fig. 6). In contrast to 
bax, bcl-x, has retained the putative effector domain S-H-C, 
but lost the entire domain S-H (7)  (Fig. 6). 
Previously, it was believed that the removal of membrane 
attachment site of bcl-2 leads to at least a partial impairment 
of its function (3), but here, we show that the membrane in- 
teraction is not obligatory. T3,  a  truncated form of bcl-2 
lacking the COOH-terminal hydrophobic tail (amino acids 
204-236) is soluble in intact cells and after in vitro synthe- 
sis, and yet is fully active in sparing neurons and fibroblasts 
from apoptosis. A major concern with this result could be 
that the T3 mutant is only marginally active but expressed 
at a much higher level than wild-type bel-2. According to our 
immunocytochemical (Fig.  3 B) and immunoblot (Fig. 4) 
studies, this appears, however, not to be the case because the 
T3  mutant was actually less expressed than its wild-type 
counterpart. 
The survival activity of  the soluble T3 mutant is not neces- 
sarily in conflict with previously published structure-func- 
tion analyses, but rather, it extends the results published to 
date: First, a bcl-2 mutant lacking the last COOH-terminal 
50  amino  acids  (our  TI)  failed  to  block  apoptosis  in 
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this is presumably caused by the lack of the two putative 
functional domain S-II (Fig. 6) rather than to the absence of 
the COOH-terminal transmembrane stretch. Second, dele- 
tion of the last 26 amino acids including the transmembrane 
domain led to a failure of bcl-2 to be inserted into micro- 
somes after in vitro transcription/translation (13). However, 
the  impact of this mutation on survival activity was  not 
reported.  This bcl-2  mutant was less truncated (by seven 
amino acids) than the herein-described T3 construct. Third, 
a recent study demonstrated that bcl-2/~, which has a mini- 
mal,  nonconserved S-II-C  domain but lacks  the  COOH- 
terminal hydrophobic stretch, is inactive in sparing 32D cells 
from apoptosis induced by IL-3 removal (58).  Surprisingly, 
the addition of a heterologous transmembrane stretch of the 
IL-2 receptors renders bcl-2/~ at least partially active. It is 
possible that the activity of the S-II segment may be unveiled 
through cooperation with additional residues derived from 
the IL-2 receptor transmembrane domain (Fig. 6). The ob- 
served partial regain of activity of the bcl-2-TM- IL-2 recep- 
tor chimeric protein would, therefore, be caused by a gain 
of function of the S-II domain rather than result from the 
membrane association. In agreement with this hypothesis 
are the negative results obtained with our DEL3 mutant, 
which  still has the transmembrane domain but lacks  the 
S-II/S-II-C domain. Fourth, Oltvai et al. (50) recently dis- 
cussed in their study that a bcl-2 mutant lacking the COOH- 
terminal 22 amino acids is cytoplasmic and partially protects 
cells from death. This mutant is even larger than T3 (by 11 
amino acids), indicating that removal of only the transmem- 
brahe stretch already renders bcl-2 soluble. Interestingly, the 
authors mention that their mutant still associates with bax 
(50), further strengthening the notion that dimerization mo- 
tifs must lie upstream of the transmembrane region. This 
finding further suggests that membrane attachment may not 
be  required  for the  interaction of bcl-2  with other bcl-2 
homologues. 
Recent results (34, 39) indicate a role for bcl-2 in an an- 
tioxidant pathway to prevent cellular damage including lipid 
peroxidation.  The protein  acts  either before or after the 
generation of 02"- and its conversion to peroxides. It was 
proposed that bcl-2 could act as a trap for oxygen radicals 
similar to glutathione. Glutathione contains a cysteine resi- 
due that acts as a hydrogen/electron donor in the reduction 
of oxygen radicals. Our mutagenesis studies speak against a 
possible analogous involvement of Cys155 or Cys226 in the 
trapping  of oxygen  radicals  by  bcl-2.  A  third  cysteine 
(Cys89) that was not mutated here is not conserved between 
human, chicken, and mouse bcl-2 (11, 18). 
O2.- radical production in vivo is localized to distinct or- 
ganelles including mitochondria,  ER,  and nuclear mem- 
branes.  Consistent with  this presumptive  function is  the 
close  association  of  bcl-2  with  mitochondrial  (35)  or 
perinuclear membranes (3, 12, 38). Our study provides evi- 
dence  that  bcl-2  may  also  fullfill  its  function  in  the 
cytoplasm. The soluble active T3.1 mutant migrates to neu- 
rites in neurons and filopodias in fibroblasts (Fig. 3). These 
structures are known to be especially vulnerable to apoptosis 
and to  H:O:  exposure:  neurites  rapidly retract  (33)  and 
fibroblasts detach from their substrate. Because of its pres- 
ence in cellular extensions, the T3.1 mutant may therefore 
efficiently protect these structures from degradation. 
In  summary, our data presented here demonstrate that 
bcl-2 can also exert its survival activity in the cytoplasm. In 
addition, they point towards putative functional motifs S-N 
and S-H/S-H-C,  which lie in highly conserved domains. This 
finding sets the stage to more precisely define the functional 
domains of bcl-2,  and to investigate their role in binding 
other bcl-2 homologues, other regulators, and effectors cru- 
cial for cell survival. 
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